PRESS RELEASE published on 06/24/2024 at 22:05, 2 years 4 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years 5 months ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
BRIEF published on 05/28/2024 at 13:05, 2 years 5 months ago CureVac annonce le dosage du premier participant à l'étude de phase 2 sur la grippe GSK Technologie ARNm Étude De Phase 2 CureVac Vaccin Contre La Grippe
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years 5 months ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years 5 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
BRIEF published on 05/23/2024 at 13:05, 2 years 5 months ago CureVac annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités Résultats Financiers Mise À Jour De L'entreprise T1 2024 CureVac Procédure Accélérée De La FDA
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years 5 months ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 6 months ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:11, 2 years 6 months ago CureVac annonce ses résultats financiers pour 2023 et des mises à jour stratégiques sur ses activités Technologie ARNm CureVac Collaborations Pharmaceutiques Vaccins Contre L'oncologie Vaccins Prophylactiques
BRIEF published on 04/24/2024 at 13:08, 2 years 6 months ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 11/05/2026 at 15:20, 13 minutes ago MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 1 hour 2 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 1 hour 8 minutes ago Polaris Renewable Energy Announces Q3 2026 Results
Published on 11/05/2026 at 14:20, 1 hour 13 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 18 minutes ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 15:10, 23 minutes ago Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 35 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 15:01, 32 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 17 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 17 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
